Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 14/20 | 0.45 |
| ▸ | CTSS | P25774 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427981 | 0.93 | CYP2D6 (0.54) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL17603553 | 0.93 | CYP2D6 (0.54) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL11126904 | 0.91 | CYP2D6 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL5199493 | 0.91 | APP (0.43) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL11126899 | 0.91 | CYP2D6 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL6829649 | 0.91 | APP (0.43) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL344846 | 0.91 | CA1 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL2385476 | 0.91 | CTSK (0.49) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL4981261 | 0.91 | CTSK (0.49) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL3682058 | 0.91 | CA1 (0.45) | CA1CA2CA7CYP2D6ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090138-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3331851-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF | Quadriga Biosciences, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017024009-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF | QUADRIGA BIOSCIENCES, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2004089362-A1 | 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| US-4415657-A | USING MICRORGANISMS FOR THE STEREOSPECIFIC HYDROGENOLYSIS OF THE DIALKYL B-PROTECTED AMINO ESTER | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BRDT, ILK, KLK3 | CA1 2184/4885CA2 3056/4885CA7 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.